Catalog # 10-2120

Bortezomib

CAS# 179324-69-7

N-(2-Pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid

MG-341, PS-341

Lot # X102736



Potent and selective proteasome inhibitor (K_i=0.6 nM). Inhibits proliferation of a number of tumor cell lines (IC_{50}=7 nM). Inhibits TNFα synthesis and FGF-induced angiogenesis. Clinically useful agent for treatment of multiple myeloma.[3] Shows promise in the treatment of neurodegenerative diseases in which low-expressing proteins such as IKAP/hELP1 in familial dysautonomia are preserved.[4] Reversible. Cell permeable.

1) Adams *et al*. (1999), *Proteasome inhibitors: a novel class of potent and effective antitumor agents*; Cancer Res., **59** 2615
2) Williams *et al*. (2003), *Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts*; Mol. Cancer Ther., **2** 835
3) Richardson *et al*. (2003), *Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers*; Cancer Control, **10** 361
4) Herve and Ibrahim (2017), *Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia*; Neurobiol. Dis., **103** 113

PHYSICAL DATA

Molecular Weight:	384.25
Molecular Formula:	$C_{19}H_{25}BN_4O_4$
Purity:	>98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (up to 50 mg/ml), Ethanol (up to 35 mg/ml)
Physical Description:	White solid
Storage and Stability:	Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in DMSO and ethanol may be stored at -20°C for up to 1 month.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462

www.focusbiomolecules.com